Badalona

• A study to investigate the novel agent BNT111 and cemiplimab in combination or as single agents in patients with advanced melanoma that has … Ended
  2023-509513-36-00 4 2021-03-24 Melanoma (Stage III and IV)
• A Phase 3 Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with … Ended
  2023-503973-39-00 5 2021-03-16 Complex Perianal Fistulas in Crohn's Disease
• A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P … Ended
  2023-509449-10-00 4 2021-03-16 Squamous cell carcinoma of the head and neck (SCCHN)
• A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and … Ended
  2023-504403-92-00 1 2021-02-15 Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymp
• Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure Ended
  2023-504165-23-00 5 2021-02-08 Acute decompensated heart failure
• A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small C … Ended
  2024-516598-60-00 5 2020-12-18 Advanced Non-Squamous Non-Small Cell Lung Cancer
• A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid Ended
  2024-510745-34-00 10 2020-11-11 Bullous Pemphigoid
• Study to evaluate the efficacy and safety of cetuximab plus irinotecan compared to investigator's choice therapy in patients with metastatic … Ended
  2024-518728-59-00 4 2020-10-23 metastatic colorectal cancer
• A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel … Ended
  2022-502480-38-00 5 2020-09-09 Non−small cell lung cancer (NSCLC)
• “A randomized phase II trial to evaluate the antitumor activity of Enzalutamide and Talazoparib (PF-06944076) for the treatment of metastati … Ended
  2023-509387-24-00 4 2020-09-02 Metastatic hormone–naïve prostate cancer (mHNPC)
• Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended
  2023-509801-59-00 5 2020-07-09 Alopecia areata
• A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung) Ended
  2023-505035-12-00 5 2020-06-12 RET fusion−positive, metastatic Non-Small Cell Lung Cancer
• Long-term Study of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis Ended
  2023-503600-83-00 5 2020-05-27 Moderate to Severe Plaque Psoriasis
• Study to compare 2 chemotherapy, one with Irinotecan liposome injection in addition to combination of chemotherapy and one with standard che … Ended
  2024-518303-21-00 5 2020-05-25 Metastatic Pancreatic Adenocarcinoma
• A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended
  2022-502482-17-00 5 2020-05-19 Non-small cell lung cancer (NSCLC)
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Ri … Ended
  2023-504036-17-00 5 2020-05-07 Chronic Lymphocytic Leukemia (CLL)
• Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer Ended
  2022-501972-25-00 5 2020-04-06 Locally Advanced Cervical Cancer
• A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi … Ended
  2023-507276-53-00 4 2020-03-23 Myelofibrosis
• Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a … Ended
  2023-508826-92-00 3 2020-02-14 Patients with PIK3CA-mutant, HER2-positive locally advanced or metasta
• Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended
  2023-508993-27-00 4 2020-01-17 Chronic myelogenous leukemia
• An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev … Ended
  2022-502361-15-00 5 2019-12-12 Moderate-to-Severe Plaque Psoriasis
• A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) … Ended
  2024-512537-33-00 5 2019-11-28 Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
• Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended
  2024-512005-87-00 4 2019-11-07 Lung Cancer
• Phase 3 study of pembrolizumab plus lenvatinib in endometrial carcinoma Ended
  2023-505614-17-00 5 2019-09-20 Participants with advanced or recurrent endometrial carcinoma

Showing 721–744 of 775 trials